01 December 2007
Pharmacokinetic principles of immunosuppressive-drugs
K. Budde, P. GlanderAnn Transplant 2008; 13(1): 12-12 :: ID: 880167
Abstract
The combination of synergistic drugs is the main strategy to prevent early acute rejection and to provide long-term effective rejection prophylaxis. Evaluation of drug concentrations to guide drug dosing is routinely established for CNIs and mTOR inhibitors. Arguments in favour of TDM are the large inter-patient variability of many immunosuppressants with their potential for severe toxicity and drug-to-drug interactions. The manuscript discusses several confounding factors, which influence the appropriate therapeutic window. These include decreasing risk of rejection over time, cumulative risk for toxicity with time, and the synergistic potential of combination immunosuppressive therapy with respect to efficacy and shared toxicities. In addition, a long list of donor and recipient characteristics have a direct or indirect effect on the therapeutic window, but have not been evaluated in rigorous, prospective trials. Unfortunately, only a very small number of adequately powered, prospective randomized trials evaluate different therapeutic windows for immunosuppressants or even the utility of therapeutic drug monitoring at all. Other problems of TDM include the inherent variability of absorption and drug levels and a suboptimal correlation between pharmacokinetic surrogate parameters and drug exposure for most drugs. Drugs with a high intra-patient day-to-day variability may be less suited for TDM compared to drugs with a high inter-patient, but low intra-patient variability. Furthermore it is not known whether the same parameter is suitable for controlling efficacy as well toxicity. With cumulative overexposure the effect of time might be more far more important than a specific level at a given time point and provides another fundamental dimension. A new approach of TDM, classified as pharmacodynamic (PD) drug monitoring, which directly reflects the drug's biological effects has been proposed to better assess the individual state of immunosuppression, however difficult test systems and lack of prospective trials limit this approach currently. Future studies have to take these considerations into account in order to better guide immunosuppression towards a more individualized therapy, which remains an important goal in transplant medicine.
Keywords: immunosuppressive therapy, Drug Monitoring, cancer, carcinomatosis, raltitrexed
169 0
In Press
02 Jun 2023 : Original article
Survival analysis of transplant-associated thrombotic microangiopathy under different diagnostic criteria a...Ann Transplant In Press; DOI: 10.12659/AOT.939890
17 May 2023 : Original article
Results of Liver Retransplantation After Rescue Hepatectomy: A Single-Center StudyAnn Transplant In Press; DOI: 10.12659/AOT.939557
10 May 2023 : Original article
Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin ...Ann Transplant In Press; DOI: 10.12659/AOT.939143
Most Viewed Current Articles
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860